Innate Pharma S.A. Announces PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027

AstraZeneca moved the expected high-level data readout for the PACIFIC-9 Phase 3 trial to the first half of 2027 from the second half of 2026. Innate Pharma said the revised timing reflects the trial’s event-driven nature; the article provides no trial results or further details.